Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

Investigational

3

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

Unknown

3

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Loevens Kemiske Fabrik Produktionsaktieselskab

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

3

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

3

ECHA (EC/EINECS)

3

EPA CompTox

3

FDA UNII

3

PUBCHEM

3

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

2

Salts, Hydrates, Esters, etc.

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 3 of 3 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

N-ETHYLMORPHOLINE

ECM0G991FQ

Export Data
Search for Structure

Status:

Investigational

Class (Stereo):

CHEMICAL (ACHIRAL)

TIMEGADINE

1XR74J44UL

Export Data
Search for Structure

Status:

Investigational

Class (Stereo):

CHEMICAL (ACHIRAL)

Timegadine Is a quinolylguanidine derivative patented by Loevens Kemiske Fabrik Produktionsaktieselskab as an anti-arthritic agent. Timegadine acts as a potent, competitive inhibitor of cyclo-oxygenase and lipo-oxygenase. Timegadine significantly inh...

ibits both the primary and secondary lesions of rats adjuvant arthritis when the treatment is initiated on the day of the disease induction and continues for 28 days. Timegadine is able specifically to prevent the development of the swelling of the non-injected paw until 28 days after the adjuvant injection when administered for 5 days prior to and 5 days after the induction of the disease, in analogy with the effect of cyclophosphamide. In clinical trials, Timegadine significantly improves both biochemical and clinical markers of disease activity, i.e. ESR, serum IgG and IgM, leukocyte and platelet counts, duration of morning stiffness, Ritchie index, number of swollen joints and pain. Timegadine treatment associated with gastrointestinal and allergic side effects.

Timegadine hydrochloride

98HR33CND7

Export Data
Search for Structure

Status:

Investigational

Class (Stereo):

CHEMICAL (ACHIRAL)

Timegadine Is a quinolylguanidine derivative patented by Loevens Kemiske Fabrik Produktionsaktieselskab as an anti-arthritic agent. Timegadine acts as a potent, competitive inhibitor of cyclo-oxygenase and lipo-oxygenase. Timegadine significantly inh...

ibits both the primary and secondary lesions of rats adjuvant arthritis when the treatment is initiated on the day of the disease induction and continues for 28 days. Timegadine is able specifically to prevent the development of the swelling of the non-injected paw until 28 days after the adjuvant injection when administered for 5 days prior to and 5 days after the induction of the disease, in analogy with the effect of cyclophosphamide. In clinical trials, Timegadine significantly improves both biochemical and clinical markers of disease activity, i.e. ESR, serum IgG and IgM, leukocyte and platelet counts, duration of morning stiffness, Ritchie index, number of swollen joints and pain. Timegadine treatment associated with gastrointestinal and allergic side effects.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1